CARB-X supports BioVersys in the fight against antimicrobial resistance with up to almost 9 million dollars
BioVersys receives CARB-X Award of up to US$ 8.92 Million for Development of Novel Antimicrobial Therapies:
Swisscom StartUp-Challenge 2019
Aurealis Pharma Announces 7.8M CHF Financing
Cellestia Biotech AG successfully closes Series A financing ...
Strekin AG today Announces the Publication of Key in vivo Da...
Bioversys at the forefront of antibiotic research